期刊
RSC ADVANCES
卷 4, 期 37, 页码 19338-19344出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4ra01485e
关键词
-
资金
- Converging Research Center Program through the National Research Foundation of Korea (NRF)-Ministry of Education, Science and Technology [2009-0081871]
- Mid-career Researcher Program through NRF-MEST [2012R1A2 A2A06045773]
- SamyangBioPharm
- National Research Foundation of Korea [2009-0081871] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Despite extensive investigations on siRNA delivery systems for the past decade, there has been no clinically available product until now. In this work, reducible hyaluronic acid (HA)-siRNA conjugate was successfully synthesized and used to make a complex with cationic solid lipid nanoparticles (CSLNs) for the development of a liver specific siRNA delivery system. The reducible HA-siRNA conjugate was synthesized by the disulfide-thiol exchange reaction between pyridyldithiol modified HA and thiolated siRNA. The remaining pyridyldithiol was further blocked with cysteine. The biomimetic CSLNs were prepared by reconstituting the composition of natural apolipoprotein-free low density lipoproteins (LDLs). The formation of the HA-siRNA/CSLN complex was confirmed by gel electrophoresis (GE), dynamic light scattering (DLS), and atomic force microscopy (AFM). The HA-siRNA/CSLN complex showed remarkably low cytotoxicity and high transfection efficiency in the presence of serum. The therapeutic index (LC50/IC50) of the HAsiRNA/ CSLN complex was statistically much higher than that of a HA-siRNA conjugate or siRNA complexed with commercially available siRNA transfection reagents like in vivo jetPEI and INTERFERin, as well as an siRNA/CSLN complex. The HA-siRNA/CSLN complex can be effectively applied as a model system for the treatment of liver diseases, such as liver fibrosis and liver cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据